businesspress24.com - Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference
 

Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference Call on Monday, August 15, 2016

ID: 1451773

(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 08/10/16 -- (NASDAQ: ATOS) announced today that it will provide a Company update and discuss second quarter 2016 financial results on Monday, August 15, 2016 at 4:30 pm eastern time. Following management''s formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-844-824-3830 and International callers should call 1-412-317-5140. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at . Details for the webcast may be found on the Company''s IR events page at .

A replay of the call will be available approximately one hour after the end of the call through September 15, 2016. The replay can be accessed via Atossa''s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10091229.

Atossa Genetics, Inc. is developing novel and locally-administered pharmaceuticals to address breast conditions, including cancer. For more information, please visit .

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa''s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa''s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.







Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902


Scott Gordon
CorProminence LLC
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516.222.2560

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569
RepliCel Life Sciences Announces Completion of the Final Injection in Its Tendon Repair Clinical Trial
Bereitgestellt von Benutzer: Marketwired
Datum: 10.08.2016 - 06:00 Uhr
Sprache: Deutsch
News-ID 1451773
Anzahl Zeichen: 2234

contact information:
Contact person:
Town:

SEATTLE, WA


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 205 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Atossa Genetics to Provide Company Update and Discuss Second Quarter Financial Results on Conference Call on Monday, August 15, 2016
"
steht unter der journalistisch-redaktionellen Verantwortung von

Atossa Genetics, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Atossa Genetics, Inc.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 84


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.